The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
Open accessAbstract
A series of recent discoveries harnessing the adaptive immune system of prokaryotes to perform targeted genome editing is having a transformative influence across the biological sciences. The discovery of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) proteins has expanded the applications of genetic research in thousands of laboratories across the globe and is redefining our approach to gene therapy. Traditional gene therapy has raised some concerns, as its reliance on viral vector delivery of therapeutic transgenes can cause both insertional oncogenesis and immunogenic toxicity. While viral vectors remain a key delivery vehicle, CRISPR technology provides a relatively simple and efficient alternative for site-specific gene editing, obliviating some concerns raised by traditional gene therapy. Although it has apparent advantages, CRISPR/Cas9 brings its own set of limitations which must be addressed for safe and efficient clinical translation. This review focuses on the evolution of gene therapy and the role of CRISPR in shifting the gene therapy paradigm. We review the emerging data of recent gene therapy trials and consider the best strategy to move forward with this powerful but still relatively new technology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Search-and-replace genome editing without double-strand breaks or donor DNA
Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1711-4 · Cited by 4,767
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR
Fang, Y., Zhang, H., Xie, J., Lin, M., Ying, L., Pang, P., & Ji, W. (2020) · Radiology · doi:10.1148/radiol.2020200432 · Cited by 3,354
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
CRISPR–Cas12-based detection of SARS-CoV-2
Broughton, J. P., Deng, X., Yu, G., Fasching, C. L., Servellita, V., Singh, J., Miao, X., Streithorst, J. A., Granados, A., Sotomayor-Gonzalez, A., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0513-4 · Cited by 2,717
High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
CRISPR RNA Maturation by Trans-Encoded Small RNA and Host Factor RNase III
Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., & Charpentier, E. (2011) · Nature · doi:10.1038/nature09886 · Cited by 2,563
Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes
Brouns, S. J. J., Jore, M. M., Lundgren, M., Westra, E. R., Slijkhuis, R. J. H., Snijders, A. P. L., Dickman, M. J., Makarova, K. S., Koonin, E. V., & van der Oost, J. (2008) · Science · doi:10.1126/science.1159689 · Cited by 2,460
Rationally engineered Cas9 nucleases with improved specificity
Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2016) · Science · doi:10.1126/science.aad5227 · Cited by 2,414
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993 · cited 1×
“Many features in an sgRNA determine specificity including the seed sequence (a 10–12 bp region proximal to PAM on 3 of spacer sequence) (29, 53), GC content (54, 55), and modifications such as 5 truncation of the sgRNA (56).”
BackgroundKosicki, M., Tomberg, K., & Bradley, A. (2018) · Nature Biotechnology · doi:10.1038/nbt.4192 · Cited by 1,883
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Base editing: precision chemistry on the genome and transcriptome of living cells
Rees, H. A., & Liu, D. R. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0059-1 · Cited by 1,675
Bolotin, A., Quinquis, B., Sorokin, A., & Ehrlich, S. D. (2005) · Microbiology · doi:10.1099/mic.0.28048-0 · Cited by 1,558
Evolved Cas9 variants with broad PAM compatibility and high DNA specificity
Hu, J. H., Miller, S. M., Geurts, M. H., Tang, W., Chen, L., Sun, N., Zeina, C. M., Gao, X., Rees, H. A., Lin, Z., et al. (2018) · Nature · doi:10.1038/nature26155 · Cited by 1,552
T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 Years
Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., et al. (1995) · Science · doi:10.1126/science.270.5235.475 · Cited by 1,550
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,498
Rosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R. A., Moen, R., Karson, E. M., Lotze, M. T., Yang, J. C., Topalian, S. L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230904 · Cited by 1,318
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
Zhang, X.-H., Tee, L. Y., Wang, X.-G., Huang, Q.-S., & Yang, S.-H. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.37 · Cited by 1,273
CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
Walton, R. T., Christie, K. A., Whittaker, M. N., & Kleinstiver, B. P. (2020) · Science · doi:10.1126/science.aba8853 · Cited by 1,233
Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery
Lin, S., Staahl, B. T., Alla, R. K., & Doudna, J. A. (2014) · eLife · doi:10.7554/elife.04766 · Cited by 1,189
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
Enhanced proofreading governs CRISPR-Cas9 targeting accuracy
Chen, J. S., Dagdas, Y. S., Kleinstiver, B. P., Welch, M. M., Sousa, A. A., Harrington, L. B., Sternberg, S. H., Joung, J. K., Yildiz, A., & Doudna, J. A. (2017) · Nature · doi:10.1038/nature24268 · Cited by 1,168
Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors
Konermann, S., Lotfy, P., Brideau, N. J., Oki, J., Shokhirev, M. N., & Hsu, P. D. (2018) · Cell · doi:10.1016/j.cell.2018.02.033 · Cited by 1,164
Maruyama, T., Dougan, S. K., Truttmann, M. C., Bilate, A. M., Ingram, J. R., & Ploegh, H. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3190 · Cited by 1,137
Engineered CRISPR-Cas9 nuclease with expanded targeting space
Nishimasu, H., Shi, X., Ishiguro, S., Gao, L., Hirano, S., Okazaki, S., Noda, T., Abudayyeh, O. O., Gootenberg, J. S., Mori, H., et al. (2018) · Science · doi:10.1126/science.aas9129 · Cited by 1,100
Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L., & Corn, J. E. (2016) · Nature Biotechnology · doi:10.1038/nbt.3481 · Cited by 1,098
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
Regulation of Homologous Recombination in Eukaryotes
Heyer, W.-D., Ehmsen, K. T., & Liu, J. (2010) · Annual Review of Genetics · doi:10.1146/annurev-genet-051710-150955 · Cited by 1,066
The epidemiology, diagnosis and treatment of COVID-19
Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y., & Li, Y. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105955 · Cited by 1,014
Correction of a pathogenic gene mutation in human embryos
Ma, H., Marti-Gutierrez, N., Park, S.-W., Wu, J., Lee, Y., Suzuki, K., Koski, A., Ji, D., Hayama, T., Ahmed, R., et al. (2017) · Nature · doi:10.1038/nature23305 · Cited by 992
p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
Ihry, R. J., Worringer, K. A., Salick, M. R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0050-6 · Cited by 978
E-CRISP: fast CRISPR target site identification
Heigwer, F., Kerr, G., & Boutros, M. (2014) · Nature Methods · doi:10.1038/nmeth.2812 · Cited by 880
Targeted Chromosomal Cleavage and Mutagenesis in Drosophila Using Zinc-Finger Nucleases
Bibikova, M., Golic, M., Golic, K. G., & Carroll, D. (2002) · Genetics · doi:10.1093/genetics/161.3.1169 · Cited by 860
Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA − Immunodeficient Patients
Bordignon, C., Notarangelo, L. D., Nobili, N., Ferrari, G., Casorati, G., Panina, P., Mazzolari, E., Maggioni, D., Rossi, C., Servida, P., et al. (1995) · Science · doi:10.1126/science.270.5235.470 · Cited by 832
Enhancing Gene Targeting with Designed Zinc Finger Nucleases
Bibikova, M., Beumer, K., Trautman, J. K., & Carroll, D. (2003) · Science · doi:10.1126/science.1079512 · Cited by 823
Mojica, F. J. M., Díez‐Villaseñor, C., Soria, E., & Juez, G. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.01838.x · Cited by 820
Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782 · cited 1×
“for the DNA:RNA heteroduplex to induce DSBs, thereby reducing OTEs while maintaining editing efficacy (38, 39).”
BackgroundEfficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects
Shen, B., Zhang, W., Zhang, J., Zhou, J., Wang, J., Chen, L., Wang, L., Hodgkins, A., Iyer, V., Huang, X., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2857 · Cited by 769
Non Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 761
Semenova, E., Jore, M. M., Datsenko, K. A., Semenova, A., Westra, E. R., Wanner, B., van der Oost, J., Brouns, S. J. J., & Severinov, K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104144108 · Cited by 726
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Regulation of Endothelial Permeability via Paracellular and Transcellular Transport Pathways
Komarova, Y., & Malik, A. B. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135833 · Cited by 641
Progress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2010) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 634
Programmable RNA recognition and cleavage by CRISPR/Cas9
O’Connell, M. R., Oakes, B. L., Sternberg, S. H., East-Seletsky, A., Kaplan, M., & Doudna, J. A. (2014) · Nature · doi:10.1038/nature13769 · Cited by 632
Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Topkar, V. V., Zheng, Z., & Joung, J. K. (2015) · Nature Biotechnology · doi:10.1038/nbt.3404 · Cited by 611
Identifying miRNAs, targets and functions
Liu, B., Li, J., & Cairns, M. J. (2014) · Briefings in Bioinformatics · doi:10.1093/bib/bbs075 · Cited by 563
Fetal hemoglobin in sickle cell anemia
Akinsheye, I., Alsultan, A., Solovieff, N., Ngo, D., Baldwin, C. T., Sebastiani, P., Chui, D. H. K., & Steinberg, M. H. (2011) · Blood · doi:10.1182/blood-2011-03-325258 · Cited by 553
Directed evolution of CRISPR-Cas9 to increase its specificity
Lee, J. K., Jeong, E., Lee, J., Jung, M., Shin, E., Kim, Y.-H., Lee, K., Jung, I., Kim, D., Kim, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05477-x · Cited by 525
Genome Engineering Using CRISPR-Cas9 System
Cong, L., & Zhang, F. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-1862-1_10 · Cited by 515
Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
Abbott, T. R., Dhamdhere, G., Liu, Y., Lin, X., Goudy, L., Zeng, L., Chemparathy, A., Chmura, S., Heaton, N. S., Debs, R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.020 · Cited by 498
A highly specific SpCas9 variant is identified by in vivo screening in yeast
Casini, A., Olivieri, M., Petris, G., Montagna, C., Reginato, G., Maule, G., Lorenzin, F., Prandi, D., Romanel, A., Demichelis, F., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4066 · Cited by 493
CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations
Cullot, G., Boutin, J., Toutain, J., Prat, F., Pennamen, P., Rooryck, C., Teichmann, M., Rousseau, E., Lamrissi-Garcia, I., Guyonnet-Duperat, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09006-2 · Cited by 474
Mojica, F. J. M., Juez, G., & Rodriguez‐Valera, F. (1993) · Molecular Microbiology · doi:10.1111/j.1365-2958.1993.tb01721.x · Cited by 349
Gene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
Origins of Programmable Nucleases for Genome Engineering
Chandrasegaran, S., & Carroll, D. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.10.014 · Cited by 325
Ye, L., Wang, J., Beyer, A. I., Teque, F., Cradick, T. J., Qi, Z., Chang, J. C., Bao, G., Muench, M. O., Yu, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407473111 · Cited by 320
Estimating the false-negative test probability of SARS-CoV-2 by RT-PCR
Wikramaratna, P. S., Paton, R. S., Ghafari, M., & Lourenço, J. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.50.2000568 · Cited by 313
Post-translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair
Gutschner, T., Haemmerle, M., Genovese, G., Draetta, G. F., & Chin, L. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.019 · Cited by 299
Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing
Wilbie, D., Walther, J., & Mastrobattista, E. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00106 · Cited by 294
A CRISPR–dCas Toolbox for Genetic Engineering and Synthetic Biology
Xu, X., & Qi, L. S. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.037 · Cited by 291
Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing
Robert, F., Barbeau, M., Éthier, S., Dostie, J., & Pelletier, J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0215-6 · Cited by 255
CRISPR’d babies: human germline genome editing in the ‘He Jiankui affair’*
Greely, H. T. (2019) · Journal of Law and the Biosciences · doi:10.1093/jlb/lsz010 · Cited by 254
Review of CRISPR/Cas9 sgRNA Design Tools
Cui, Y., Xu, J., Cheng, M., Liao, X., & Peng, S. (2018) · Interdisciplinary Sciences: Computational Life Sciences · doi:10.1007/s12539-018-0298-z · Cited by 245
Gene therapy for cancer: present status and future perspective
Amer, M. H. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-27 · Cited by 244
Minimal PAM specificity of a highly similar SpCas9 ortholog
Chatterjee, P., Jakimo, N., & Jacobson, J. M. (2018) · Science Advances · doi:10.1126/sciadv.aau0766 · Cited by 228
CRISPR base editors: genome editing without double-stranded breaks
Eid, A., Alshareef, S., & Mahfouz, M. M. (2018) · Biochemical Journal · doi:10.1042/bcj20170793 · Cited by 224
Nishiyama, J., Mikuni, T., & Yasuda, R. (2017) · Neuron · doi:10.1016/j.neuron.2017.10.004 · Cited by 215
Hu, Z., Yu, L., Zhu, D., Ding, W., Wang, X., Zhang, C., Wang, L., Jiang, X., Shen, H., He, D., et al. (2014) · BioMed Research International · doi:10.1155/2014/612823 · Cited by 211
Alkhatib, G. (2009) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328324bbec · Cited by 208
Engineered materials for in vivo delivery of genome-editing machinery
Tong, S., Moyo, B., Lee, C. M., Leong, K., & Bao, G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0145-9 · Cited by 205
Structural Plasticity of PAM Recognition by Engineered Variants of the RNA-Guided Endonuclease Cas9
Anders, C., Bargsten, K., & Jinek, M. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.020 · Cited by 201
RNA-dependent RNA targeting by CRISPR-Cas9
Strutt, S. C., Torrez, R. M., Kaya, E., Negrete, O. A., & Doudna, J. A. (2018) · eLife · doi:10.7554/elife.32724 · Cited by 186
Gammaretroviral Vectors: Biology, Technology and Application
Maetzig, T., Galla, M., Baum, C., & Schambach, A. (2011) · Viruses · doi:10.3390/v3060677 · Cited by 184
Sequence features associated with the cleavage efficiency of CRISPR/Cas9 system
Liu, X., Homma, A., Sayadi, J., Yang, S., Ohashi, J., & Takumi, T. (2016) · Scientific Reports · doi:10.1038/srep19675 · Cited by 166
Lau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161
Zhang, Y., Li, H., Min, Y.-L., Sanchez-Ortiz, E., Huang, J., Mireault, A. A., Shelton, J. M., Kim, J., Mammen, P. P. A., Bassel-Duby, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay6812 · Cited by 161
SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective
Sironi, M., Hasnain, S. E., Rosenthal, B. M., Phan, T. G., Luciani, F., Shaw, M., Sallum, M. A. M., Mirhashemi, M. E., Morand, S., & Gónzález‐Candelas, F. (2020) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2020.104384 · Cited by 154
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
Prakash, V., Moore, M., & Yáñez‐Muñoz, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.5 · Cited by 150
Wyvekens, N., Topkar, V. V., Khayter, C., Joung, J. K., & Tsai, S. Q. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.084 · Cited by 149
BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations
Basak, A., Hancarova, M., Ulirsch, J. C., Balci, T. B., Trkova, M., Pelisek, M., Vlckova, M., Muzikova, K., Cermak, J., Trka, J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81163 · Cited by 147
Kim, H. K., Lee, S., Kim, Y., Park, J., Min, S., Choi, J. W., Huang, T. P., Yoon, S., Liu, D. R., & Kim, H. H. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0505-1 · Cited by 145 · cited 1×
“A side by side comparison of both variants revealed that while SpCas9-NG had a broader PAM recognition, xCas9 had the lowest OTE in human cells (63).”
BackgroundPankowicz, F. P., Barzi, M., Legras, X. D., Hubert, L., Tian, M., Tomolonis, J., Ravishankar, M., Sun, Q., Yang, D., Borowiak, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12642 · Cited by 144
Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage
Kulcsár, P. I., Tálas, A., Huszár, K., Ligeti, Z., Tóth, E., Weinhardt, N., Fodor, E., & Welker, E. (2017) · Genome biology · doi:10.1186/s13059-017-1318-8 · Cited by 144
Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System
Moses, C., Nugent, F., Waryah, C. B., García‐Bloj, B., Harvey, A. R., & Blancafort, P. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.12.003 · Cited by 143
Delivery of CRISPR/Cas9 for therapeutic genome editing
Xu, X., Wan, T., Xin, H., Li, D., Pan, H., Wu, J., & Ping, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3107 · Cited by 134
Moreno, A. M., Palmer, N. D., Alemán, F., Chen, G., Pla, A., Jiang, N. J., Chew, W. L., Law, M., & Mali, P. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0431-2 · Cited by 134
Death but one unintended consequence of gene-therapy trial.
Sibbald, B. (2001) · PubMed · Cited by 124
Nunes, F. A., Furth, E. E., Wilson, J. M., & Raper, S. E. (1999) · Human Gene Therapy · doi:10.1089/10430349950016852 · Cited by 121
Rationally engineered Staphylococcus aureus Cas9 nucleases with high genome-wide specificity
Tan, Y., Chu, A. H. Y., Bao, S., Hoang, D. A., Kebede, F. T., Xiong, W., Ji, M., Shi, J., & Zheng, Z. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906843116 · Cited by 118
Ling, X., Xie, B., Gao, X., Chang, L., Zheng, W., Chen, H., Huang, Y., Tan, L., Li, M., & Liu, T. (2020) · Science Advances · doi:10.1126/sciadv.aaz0051 · Cited by 111
Lomova, A., Clark, D. N., Campo-Fernández, B., Flores, C., Kaufman, M. L., Fitz‐Gibbon, S. T., Wang, X., Miyahira, E., Brown, D., DeWitt, M. A., et al. (2018) · Stem Cells · doi:10.1002/stem.2935 · Cited by 102
First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?
Baylis, F. E., & McLeod, M. (2017) · Current Gene Therapy · doi:10.2174/1566523217666171121165935 · Cited by 98
Generalizable sgRNA design for improved CRISPR/Cas9 editing efficiency
Hiranniramol, K., Chen, Y., Liu, W., & Wang, X. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa041 · Cited by 97
Insertional oncogenesis in gene therapy: how much of a risk?
Sadelain, M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302243 · Cited by 92
Evaluating the Efficiency of gRNAs in CRISPR/Cas9 Mediated Genome Editing in Poplars
Brügmann, T., Deecke, K., & Fladung, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153623 · Cited by 85
Bridge helix arginines play a critical role in Cas9 sensitivity to mismatches
Bratovič, M., Fonfara, I., Chylinski, K., Gálvez, E. J. C., Sullivan, T. J., Boerno, S. T., Timmermann, B., Boettcher, M., & Charpentier, E. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0490-4 · Cited by 71
Regulation of the fetal hemoglobin silencing factor BCL11A
Basak, A., & Sankaran, V. G. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13024 · Cited by 70
Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles
Yu, K., Natanson, H., & Dunbar, C. E. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.107 · Cited by 62
Cytosine base editor 4 but not adenine base editor generates off-target mutations in mouse embryos
Lee, H., Smith, H. E., Liu, C., Willi, M., & Hennighausen, L. G. (2020) · Communications Biology · doi:10.1038/s42003-019-0745-3 · Cited by 61
Suppressing Ku70/Ku80 expression elevates homology-directed repair efficiency in primary fibroblasts
Li, G., Liu, D., Zhang, X., Quan, R., Zhong, C., Mo, J., Huang, Y., Wang, H., Xiao-fang, R. U. A. N., Xu, Z., et al. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.04.011 · Cited by 56
Targeted gene therapies: tools, applications, optimization
Humbert, O., Davis, L., & Maizels, N. (2012) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.658112 · Cited by 50
Kulcsár, P. I., Tálas, A., Tóth, E., Nyeste, A., Ligeti, Z., Welker, Z., & Welker, E. (2020) · Nature Communications · doi:10.1038/s41467-020-15021-5 · Cited by 45
Overview of Drug Delivery and Alternative Methods to Electroporation
Hui, S. W. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-194-9_6 · Cited by 44
Luan, B., Xu, G., Feng, M., Cong, L., & Zhou, R. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13144 · Cited by 43
Benchmarking CRISPR on-target sgRNA design
Yan, J., Chuai, G., Zhou, C., Zhu, C., Yang, J., Zhang, C., Gu, F., Xu, H., Wei, J., & Liu, Q. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx001 · Cited by 42
Tissue-specific gene targeting using CRISPR/Cas9
Ablain, J., & Zon, L. I. (2016) · Methods in cell biology · doi:10.1016/bs.mcb.2016.03.004 · Cited by 35
Did CRISPR help—or harm—the first-ever gene-edited babies?
Cohen, J. (2019) · Science · doi:10.1126/science.aay9569 · Cited by 27
Gene Therapy for SCID-X1: Round 2
Herzog, R. W. (2010) · Molecular Therapy · doi:10.1038/mt.2010.228 · Cited by 26
Xin, H., Wan, T. Y., & Yuan, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0044-y · Cited by 23
Lin, S., Staahl, B. T., Alla, R. K., & Doudna, J. A. (2014) · doi:10.7554/elife.04766.010 · Cited by 15
Larochelle, S. (2018) · Nature Methods · doi:10.1038/nmeth.4681 · Cited by 14
Cited by
CRISPR in cancer biology and therapy
Katti, A., Diaz, B. J., Caragine, C. M., Sanjana, N. E., & Dow, L. E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00441-w · Cited by 424
Nanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 332
Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing
Li, B., Manan, R. S., Liang, S.-Q., Gordon, A., Jiang, A., Varley, A., Gao, G., Langer, R., Xue, W., & Anderson, D. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01679-x · Cited by 295
The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits
Hinney, A., Körner, A., & Fischer-Posovszky, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00716-0 · Cited by 101
Lohia, A., Sahel, D. K., Salman, M., Singh, V., Mariappan, I., Mittal, A., & Chitkara, D. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.02.001 · Cited by 33
Metadata
- Authors
- Uddin, F., Rudin, C. M., & Sen, T.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-07
- Volume
- 10
- Pages
- 1387-1387
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3047882216
- Cited by
- 581
- References
- 118
- FWCI
- 17.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.